1.00 / AMA PRA Category 1 CreditTM 1.00 / CE for Nurses
Provided by Physicians' Education Resource®, LLC (PER®)
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Idiopathic pulmonary fibrosis (IPF) is a rare and progressive fibrotic lung disease with a median survival of 2 ½ to 5 years, which is worse than most cancers. With nonspecific signs and symptoms including dyspnea and cough, diagnosis is challenging and often delayed. While there is no cure, antifibrotic therapies can slow or halt disease progression and, along with supportive measures, improve patients' quality of life.
During this Patient Caregiver Connection® Medical Crossfire®, a multidisciplinary panel of expert faculty will share their insights on early, differential diagnosis and discuss clinical practice guideline updates which include conditional recommendations for the antifibrotic therapies pirfenidone and nintedanib. Faculty will then elaborate on the need for a multidisciplinary ‘ABCDE’ approach to address not only the range of comorbidities associated with IPF, but to provide comfort care that assesses and focuses on individual patient needs. This activity is enhanced with a patient’s own story and perspective, from delays in diagnosis to daily challenges and advice for anyone burdened with a diagnosis of IPF.
This CME/CE activity is intended for IPF specialists, primary care physicians, physician assistants, nurse practitioners, nurses, and other clinicians who treat patients with IPF.
After completing this activity, clinicians should be better able to:
List strategies for confirming an IPF diagnosis, including the utility of high-resolution computed tomography and surgical lung biopsy
Distinguish idiopathic from non-idiopathic forms by applying appropriate diagnostic testing, such as high-resolution CT scanning, to characterize distribution of fibrosis and inflammation
Apply current guidelines and new clinical evidence to develop a patient-centered, team approach plan for patients with IPF
Discuss new evidence and the status of emerging treatments for patients with IPF
Describe strategies to engage patients and facilitate a multidisciplinary approach to the management of IPF and associated comorbidities
Conflict Of Interest Disclosure Policy
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER is required by ACCME to resolve all COI. PER has identified and resolved all COI prior to the start of this activity by using a multistep process.
Stephen Brunton, MD Executive Vice President Primary Care Education Consortium Clinical Family Practice Glendale and Downey, CA
Dr. Brunton has no relevant financial relationships with commercial interests.
Louis Kuritzky, MD Clinical Assistant Professor Emeritus University of Florida Gainesville, FL
Dr. Kuritzky has no relevant financial relationships with commercial interests.
Steven Nathan, MD Medical Director, Advanced Lung Disease and Lung Transplant Program Professor of Medicine Virginia Commonwealth University-Inova Falls Church, VA
Dr. Nathan discloses the following: Grant/research support, consultant, member of speakers bureau: Boehringer Ingelheim, Inc. and Roche-Genentech.
Mary M. Salvatore, MD, MBA Associate Professor of Radiology Mount Sinai New York, NY
Dr. Salvatore discloses the following: Member of speakers bureau: Genentech, Boehringer Ingelheim Inc. and Rockpointe.
Accredited Provider Disclosure
The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with commercial interests to disclose.
AMA PRA Category 1 Credit(s)TM
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Physicians' Education Resource®, LLC is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing Nursing (CBRN). Provider #16669, for 1.00 Contact Hour.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
In order to receive credit, participants must complete the pre-assessment questions, view the activity in its entirety, and complete the post-test and program evaluation. Participants must also score at least 70% on the post-test. You will receive a digital copy of your credit certificate at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.